About: Matrix metalloproteinase 3 as a valuable marker for patients with COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Matrix metalloproteinase 3 as a valuable marker for patients with COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Matrix metalloproteinase 3 as a valuable marker for patients with COVID‐19
Creator	Hu, Yan Yi, Fan Gang, \| Li, Qiong Pan, \| Shen, Ge Shi, Shengjie Su, Min Zhou, \| Xie, \| Zeng, Ziyan
source	Medline; PMC
abstract	The situation of the coronavirus disease 2019 (COVID‐19) continues to evolve, our study explored the significance of serum levels of matrix metalloproteinase 3 (MMP3) as a marker for patients with COVID‐19. Sixty‐two COVID‐19 patients in the First Hospital of Hunan University of Chinese Medicine and Loudi Center for Diseases Prevention and Control, from January to March 2020, were sampled as the novel coronavirus pneumonia infected group. One hundred and thirty‐one cases from the First Hospital of Hunan University of Chinese Medicine, including 67 healthy individuals and 64 non‐COVID‐19 inpatients, served as the noninfected group. Approximately every 5 days, sera from 20 cases were collected and analyzed three times, using an automatic biochemical analyzer, to detect serum MMP3 concentrations. Correlation was analyzed between MMP3 and other proinflammatory cytokines. Following normality tests, differences in serum MMP3 levels between the infected and noninfected group were analyzed via SPSS (version 25.0) software, using the Wilcoxon rank sum test. The MMP3 concentration was 44.44 (23.46 ~ 72.12) ng/mL in the infected group and 32.42 (28.16 ~ 41.21) ng/mL in the noninfected group. The difference between the two groups was statistically significant (Z = −2.799, P = .005 < .05). A positive correlation was found between MMP3 and interleukin 1β (IL‐1β; r = .681, P = .000 < .05), and IL‐6 (r = .529, P = .002 < .05). Serum MMP3 concentration, measured over three separate time points, were 55.98 (30.80 ~ 75.97) ng/mL, 34.84 (0.00 ~ 51.84) ng/mL, and 5.71 (0.00 ~ 40.46) ng/mL, respectively. Detection of serum MMP3 levels may play an important role in the development of therapeutic approaches for COVID‐19 and may indicate the severity of disease.
has issue date	2020-07-11(xsd:dateTime)
bibo:doi	10.1002/jmv.26235
bibo:pmid	32603484
has license	no-cc
sha1sum (hex)	b81c3c03b5750438cb60df31418ac7d58abf20ca
schema:url	https://doi.org/10.1002/jmv.26235
resource representing a document's title	Matrix metalloproteinase 3 as a valuable marker for patients with COVID‐19
has PubMed Central identifier	PMC7362036
has PubMed identifier	32603484
schema:publication	J Med Virol
resource representing a document's body	covid:b81c3c03b5750438cb60df31418ac7d58abf20ca#body_text
is schema:about of	named entity 'PNEUMONIA' named entity 'EVOLVE' named entity 'evolve' named entity 'coronavirus' named entity 'COVID' named entity 'COVID-19' named entity 'immune responses' named entity 'MMP3' named entity 'nucleic acid test' named entity '25.0' named entity 'IL-6' named entity 'positive correlation' named entity 'COVID-19' named entity 'COVID' named entity 'MMP3' named entity 'MMP3' named entity 'Wilcoxon rank sum test' named entity 'MMP3' named entity 'Normality tests' named entity 'IL-6' named entity 'MMP3' named entity 'MMP3' named entity '25.0' named entity 'serum' named entity 'COVID' named entity 'IL-6' named entity 'hydrothorax' named entity 'statistically significant' named entity 'MMPs' named entity 'IL-6' named entity 'MMP3' named entity 'serum levels' named entity 'statistical significance' named entity 'SARS-CoV-2' named entity 'Wilcoxon rank sum test' named entity 'IgM antibodies' named entity 'Wilcoxon rank sum test' named entity 'immunoglobulin' named entity 'MMPs' named entity 'COVID' named entity 'IL-1β' named entity 'test kits' named entity 'standard deviation' named entity 'MMP3' named entity 'MMP-3' named entity 'IgG' named entity 'ng/mL' named entity 'MMPs' named entity 'serum' named entity 'SPSS' named entity 'pulmonary fibrosis' named entity 'MMP3' named entity 'biochemical' named entity 'ng/mL' named entity 'MMP3' named entity 'endopeptidases' named entity 'fever' named entity 'proinflammatory cytokines' named entity 'MMP3' named entity 'infection' named entity 'Interleukin 1β' named entity 'SARS-CoV-2' named entity 'Serum' named entity 'MMP3' named entity 'infection' named entity 'ascites' named entity 'serum' named entity 'Beijing' named entity 'pneumonia' named entity 'serum' named entity 'lung cancer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software